Apogent Technologies Inc. Announces Acquisition Of Advanced Biotechnologies Limited

Apr 10, 2001, 01:00 ET from Apogent Technologies Inc.

    PORTSMOUTH, N.H., April 10 /PRNewswire/ --
 Apogent Technologies Inc. (NYSE:   AOT) announced today that it acquired
 Advanced Biotechnologies Limited ("ABgene") headquartered in Epsom, England.
 ABgene was founded in 1989 and has become a leading manufacturer of a
 comprehensive range of molecular biology reagents and special plastic
 consumables for the life sciences market.  ABgene's sales revenues for the
 year just ended were approximately $21 million, with an anticipated growth
 rate in excess of 20% for the next few years.
     ABgene provides in-depth knowledge and leading products for the genomics,
 proteomics, high throughput screening (HTS) and drug discovery markets.  The
 company's product portfolio enables researchers to increase throughput and
 lower costs, while accelerating development of new pharmaceutical drugs.
 Abgene has a strong record of product innovation.  The company recently
 extended its PCR plastics line and launched three new products including:  an
 Automated Laboratory Plate Sealer, a two dimensional data matrix coding system
 for compound storage and sample tracking, and a novel "Hot Start" enzyme for
 DNA amplification.  Paul Day, ABgene's Managing Director stated, "The
 acquisition by Apogent will enable us to benefit from the synergies associated
 with being part of a larger group so that we can further enhance our rapid
 growth in the life sciences market.
     The acquisition of ABgene will strengthen Apogent's product offerings in
 the genomic research consumables and PCR markets.  ABgene's product lines are
 a natural extension to those currently sold by other Apogent businesses
 including products sold by Molecular BioProducts, Matrix Technologies, Robbins
 Scientific, Genevac, BioRobotics, Nunc and Erie Scientific.  Verner Andersen,
 President of Apogent's Labware and Life Sciences Group stated that "ABgene's
 leading market position and strong relationships with key OEMs will strengthen
 Apogent's role as a prominent supplier of tools for genomic and proteomic
 research has been further strengthened by this acquisition."
     Commenting on the ABgene acquisition, Apogent's President and Chief
 Executive Officer, Frank H. Jellinek, Jr. stated, "ABgene's strong brand
 recognition in these rapidly-growing segments of the life sciences market,
 combined with our recent acquisition of BioRobotics, supports Apogent's
 strategic focus on achieving a significant presence in the genomics,
 proteomics and drug discovery markets.  With this acquisition, Apogent will
 now supply approximately $200 million of products to these markets annually
 giving us tremendous visibility and momentum."
 
     Upcoming Events
     On Tuesday, April 24, 2001 at 11 A.M. EDT, Apogent expects to host a
 conference call to discuss its second fiscal quarter financial results for the
 period ended March 31, 2001.
     The dial-in numbers for the teleconference will be:
 
     Domestic Callers          (800) 582-6982
     International Callers     (212) 748-2711
 
     The conference call will also be audio webcast on Apogent's website in the
 Investor Relations section at www.apogent.com .
     On Tuesday, May 15, 2001, Apogent management will be presenting at the
 Robert W. Baird Growth Stock Conference at 1:35 PM CDT at the Four Seasons
 Hotel in Chicago, Illinois.  For further information on this presentation
 including a copy of the written presentation materials, again please visit the
 Investor Relations section of Apogent's website at www.apogent.com .
 
     Business Description
     Apogent's subsidiaries design, manufacture and market value-added
 laboratory and life science products for the clinical, research and industrial
 markets, worldwide.  The Company's lines of business include Labware and Life
 Sciences, Diagnostics and Microbiology, Clinical and Industrial, and
 Laboratory Equipment.
     Apogent's broad array of industry leading products includes Nalge Nunc
 International reusable and disposable multi-well plates and plastic labware;
 Microgenics drug testing products; Applied Biotech rapid diagnostic tests;
 Erie Scientific coated and printed glass for clinical diagnostics and
 microarray applications; Richard-Allan Scientific histology and
 immunohistochemistry consumables and equipment; and Barnstead Thermolyne
 laboratory equipment and water systems.
 
     Note Regarding Forward-Looking Statements
     This press release contains forward-looking statements as defined under
 Federal securities laws, including statements concerning the Company's
 strategic and financial goals and market growth that involve risks and
 uncertainties.  These and other statements that relate to future results and
 events are based on the Company's current expectations.  Actual results may
 differ materially from those presently anticipated.  Factors that could cause
 actual results to differ materially include the "Cautionary Factors" contained
 in the Company's Form 10-K filed with the Securities and Exchange Commission
 for the fiscal year ended September 30, 2000 and its subsequent report(s) on
 Form 10Q.  We undertake no obligation to publicly update any forward-looking
 statement, whether as a result of new information, future events or otherwise.
 
 

SOURCE Apogent Technologies Inc.
    PORTSMOUTH, N.H., April 10 /PRNewswire/ --
 Apogent Technologies Inc. (NYSE:   AOT) announced today that it acquired
 Advanced Biotechnologies Limited ("ABgene") headquartered in Epsom, England.
 ABgene was founded in 1989 and has become a leading manufacturer of a
 comprehensive range of molecular biology reagents and special plastic
 consumables for the life sciences market.  ABgene's sales revenues for the
 year just ended were approximately $21 million, with an anticipated growth
 rate in excess of 20% for the next few years.
     ABgene provides in-depth knowledge and leading products for the genomics,
 proteomics, high throughput screening (HTS) and drug discovery markets.  The
 company's product portfolio enables researchers to increase throughput and
 lower costs, while accelerating development of new pharmaceutical drugs.
 Abgene has a strong record of product innovation.  The company recently
 extended its PCR plastics line and launched three new products including:  an
 Automated Laboratory Plate Sealer, a two dimensional data matrix coding system
 for compound storage and sample tracking, and a novel "Hot Start" enzyme for
 DNA amplification.  Paul Day, ABgene's Managing Director stated, "The
 acquisition by Apogent will enable us to benefit from the synergies associated
 with being part of a larger group so that we can further enhance our rapid
 growth in the life sciences market.
     The acquisition of ABgene will strengthen Apogent's product offerings in
 the genomic research consumables and PCR markets.  ABgene's product lines are
 a natural extension to those currently sold by other Apogent businesses
 including products sold by Molecular BioProducts, Matrix Technologies, Robbins
 Scientific, Genevac, BioRobotics, Nunc and Erie Scientific.  Verner Andersen,
 President of Apogent's Labware and Life Sciences Group stated that "ABgene's
 leading market position and strong relationships with key OEMs will strengthen
 Apogent's role as a prominent supplier of tools for genomic and proteomic
 research has been further strengthened by this acquisition."
     Commenting on the ABgene acquisition, Apogent's President and Chief
 Executive Officer, Frank H. Jellinek, Jr. stated, "ABgene's strong brand
 recognition in these rapidly-growing segments of the life sciences market,
 combined with our recent acquisition of BioRobotics, supports Apogent's
 strategic focus on achieving a significant presence in the genomics,
 proteomics and drug discovery markets.  With this acquisition, Apogent will
 now supply approximately $200 million of products to these markets annually
 giving us tremendous visibility and momentum."
 
     Upcoming Events
     On Tuesday, April 24, 2001 at 11 A.M. EDT, Apogent expects to host a
 conference call to discuss its second fiscal quarter financial results for the
 period ended March 31, 2001.
     The dial-in numbers for the teleconference will be:
 
     Domestic Callers          (800) 582-6982
     International Callers     (212) 748-2711
 
     The conference call will also be audio webcast on Apogent's website in the
 Investor Relations section at www.apogent.com .
     On Tuesday, May 15, 2001, Apogent management will be presenting at the
 Robert W. Baird Growth Stock Conference at 1:35 PM CDT at the Four Seasons
 Hotel in Chicago, Illinois.  For further information on this presentation
 including a copy of the written presentation materials, again please visit the
 Investor Relations section of Apogent's website at www.apogent.com .
 
     Business Description
     Apogent's subsidiaries design, manufacture and market value-added
 laboratory and life science products for the clinical, research and industrial
 markets, worldwide.  The Company's lines of business include Labware and Life
 Sciences, Diagnostics and Microbiology, Clinical and Industrial, and
 Laboratory Equipment.
     Apogent's broad array of industry leading products includes Nalge Nunc
 International reusable and disposable multi-well plates and plastic labware;
 Microgenics drug testing products; Applied Biotech rapid diagnostic tests;
 Erie Scientific coated and printed glass for clinical diagnostics and
 microarray applications; Richard-Allan Scientific histology and
 immunohistochemistry consumables and equipment; and Barnstead Thermolyne
 laboratory equipment and water systems.
 
     Note Regarding Forward-Looking Statements
     This press release contains forward-looking statements as defined under
 Federal securities laws, including statements concerning the Company's
 strategic and financial goals and market growth that involve risks and
 uncertainties.  These and other statements that relate to future results and
 events are based on the Company's current expectations.  Actual results may
 differ materially from those presently anticipated.  Factors that could cause
 actual results to differ materially include the "Cautionary Factors" contained
 in the Company's Form 10-K filed with the Securities and Exchange Commission
 for the fiscal year ended September 30, 2000 and its subsequent report(s) on
 Form 10Q.  We undertake no obligation to publicly update any forward-looking
 statement, whether as a result of new information, future events or otherwise.
 
 SOURCE  Apogent Technologies Inc.